Johnson & Johnson $JNJ Shares Sold by HC Advisors LLC

HC Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 9.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,335 shares of the company’s stock after selling 141 shares during the quarter. HC Advisors LLC’s holdings in Johnson & Johnson were worth $221,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Highline Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $47,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the first quarter worth $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on JNJ. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Morgan Stanley increased their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Finally, Barclays increased their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $174.50.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ stock opened at $176.26 on Tuesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $177.57. The stock has a market cap of $424.49 billion, a P/E ratio of 18.85, a P/E/G ratio of 2.25 and a beta of 0.41. The business has a fifty day simple moving average of $161.70 and a 200-day simple moving average of $158.60. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $2.82 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.